Amati AIM VCT (AMAT) Competitors

Alliance Pharma (LON:APH) and Amati AIM VCT (LON:AMAT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.

Does the MarketBeat Community believe in APH or AMAT?

Alliance Pharma received 186 more outperform votes than Amati AIM VCT when rated by MarketBeat users. However, 70.83% of users gave Amati AIM VCT an outperform vote while only 61.89% of users gave Alliance Pharma an outperform vote.

Company	Underperform	Outperform
Alliance Pharma	Outperform Votes 203 61.89%	Underperform Votes 125 38.11%
Amati AIM VCT	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%

Is APH or AMAT a better dividend stock?

Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 8.1%. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Amati AIM VCT pays out -68.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.

Do institutionals and insiders have more ownership in APH or AMAT?

66.3% of Alliance Pharma shares are held by institutional investors. 12.0% of Alliance Pharma shares are held by company insiders. Comparatively, 0.5% of Amati AIM VCT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is APH or AMAT more profitable?

Amati AIM VCT has a net margin of 190.46% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -14.97% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alliance Pharma	-18.34%	-15.24%	5.98%
Amati AIM VCT	190.46%	-14.97%	-4.56%

Do analysts prefer APH or AMAT?

Alliance Pharma currently has a consensus price target of GBX 6,250, suggesting a potential upside of 9,559.97%. Given Alliance Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Alliance Pharma is more favorable than Amati AIM VCT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alliance Pharma	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amati AIM VCT	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to APH or AMAT?

In the previous week, Alliance Pharma's average media sentiment score of 0.00 equaled Amati AIM VCT'saverage media sentiment score.

Company	Overall Sentiment
Alliance Pharma	Neutral
Amati AIM VCT	Neutral

Which has more volatility & risk, APH or AMAT?

Alliance Pharma has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Amati AIM VCT has a beta of 0.54, indicating that its share price is 46% less volatile than the S&P 500.

Which has stronger earnings and valuation, APH or AMAT?

Amati AIM VCT has lower revenue, but higher earnings than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alliance Pharma	£183.50M	1.91	-£33.65M	-£6.20	-10.43
Amati AIM VCT	-£5.65M	-16.12	-£10.76M	-£7.28	-8.52

Summary

Alliance Pharma beats Amati AIM VCT on 10 of the 17 factors compared between the two stocks.